Sunit Das




Sunit Das is a neurosurgeon and scientist at St. Michael’s Hospital and the Hospital for Sick Kids, and Associate Professor in the Department of Surgery at the University of Toronto. He currently serves as the CNS Tumours Lead at Ontario Health (Cancer Care Ontario). Dr. Das studied English Literature at the University of Michigan and Philosophy at Harvard University before moving to Chicago for medical school at Northwestern University. He completed his doctoral studies in Neurobiology at the National Institutes of Health, where he studied the molecular processes that underlie adult neurogenesis in the lab of Dr. ZuHang Sheng. He returned to Chicago for his neurosurgical residency, during which time he also began work on cancer stem cells in primary brain tumours in the lab of Dr. John Kessler. He was recruited to the University of Toronto in 2010. Dr. Das’s clinical practice is focused on the care of patients with benign and malignant brain tumours. His laboratory in the Arthur and Sonia Labatt Brain Tumour Centre at the Hospital for Sick Kids focuses on the molecular and genetic mechanisms that regulate cellular plasticity, fate specification and treatment resistance in glioblastoma. His research group at the Li Ka Shing Knowledge Institute is focused on using real-world data and meta-analysis for knowledge translation. His work has been published in many high impact journals, including Nature, Nature Genetics, Cell Stem Cell, Cancer Cell, JAMA, JAMA Neurology, and the New England Journal of Medicine. In 2017, Dr. Das joined the Centre for Ethics at the University of Toronto. His work at the Centre for Ethics focuses on the interface of AI with medicine, issues that underlie professional identity in medical practice, and the ethics of surgical innovation. Dr. Das was recently named a Senior Fellow at Massey College.

Recent Publications

  1. Nduom, EK, Gephart, MH, Chheda, MG, Suva, ML, Amankulor, N, Battiste, JD et al.. Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators. Neurosurgery. 2021; :. doi: 10.1093/neuros/nyab063. PubMed PMID:33862619 .
  2. Maralani, PJ, Myrehaug, S, Mehrabian, H, Chan, AK, Wintermark, M, Heyn, C et al.. ADC, D, f dataset calculated through the simplified IVIM model, with MGMT promoter methylation, age, and ECOG, in 38 patients with wildtype IDH glioblastoma. Data Brief. 2021;35 :106950. doi: 10.1016/j.dib.2021.106950. PubMed PMID:33850982 PubMed Central PMC8039816.
  3. Shahzad, U, Krumholtz, S, Rutka, JT, Das, S. Noncoding RNAs in Glioblastoma: Emerging Biological Concepts and Potential Therapeutic Implications. Cancers (Basel). 2021;13 (7):. doi: 10.3390/cancers13071555. PubMed PMID:33800703 PubMed Central PMC8037102.
  4. Erickson, AW, Habbous, S, Hoey, C, Jerzak, KJ, Das, S. Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis. NPJ Breast Cancer. 2021;7 (1):17. doi: 10.1038/s41523-021-00220-0. PubMed PMID:33602948 PubMed Central PMC7892568.
  5. Habbous, S, Forster, K, Darling, G, Jerzak, K, Holloway, CMB, Sahgal, A et al.. Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a population-based study. Neurooncol Adv. ;3 (1):vdaa178. doi: 10.1093/noajnl/vdaa178. PubMed PMID:33585818 PubMed Central PMC7872008.
  6. Sachamitr, P, Ho, JC, Ciamponi, FE, Ba-Alawi, W, Coutinho, FJ, Guilhamon, P et al.. PRMT5 inhibition disrupts splicing and stemness in glioblastoma. Nat Commun. 2021;12 (1):979. doi: 10.1038/s41467-021-21204-5. PubMed PMID:33579912 PubMed Central PMC7881162.
  7. Zeng, KL, Sahgal, A, Husain, ZA, Myrehaug, S, Tseng, CL, Detsky, J et al.. Local control and patterns of failure for "Radioresistant" spinal metastases following stereotactic body radiotherapy compared to a "Radiosensitive" reference. J Neurooncol. 2021;152 (1):173-182. doi: 10.1007/s11060-020-03691-6. PubMed PMID:33453002 .
  8. Jabehdar Maralani, P, Myrehaug, S, Mehrabian, H, Chan, AKM, Wintermark, M, Heyn, C et al.. Intravoxel incoherent motion (IVIM) modeling of diffusion MRI during chemoradiation predicts therapeutic response in IDH wildtype glioblastoma. Radiother Oncol. 2021;156 :258-265. doi: 10.1016/j.radonc.2020.12.037. PubMed PMID:33418005 .
  9. Kuksis, M, Gao, Y, Tran, W, Hoey, C, Kiss, A, Komorowski, AS et al.. The Incidence of Brain Metastases Among Patients with Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. Neuro Oncol. 2020; :. doi: 10.1093/neuonc/noaa285. PubMed PMID:33367836 .
  10. Erickson, AW, Ghodrati, F, Habbous, S, Jerzak, KJ, Sahgal, A, Ahluwalia, MS et al.. HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis. Neurooncol Adv. ;2 (1):vdaa136. doi: 10.1093/noajnl/vdaa136. PubMed PMID:33305268 PubMed Central PMC7720818.
Search PubMed

Affiliations & Other Activities

  • Associate Professor, Division of Neurosurgery, Department of Surgery, St. Michael’s Hospital
  • Adjunct Scientist, Brain Tumour Research Centre, Hospital for Sick Children